New combo therapy aims to beat tough blood cancer

NCT ID NCT06712121

Recruiting now Disease control Sponsor: Seoul National University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether combining two drugs, venetoclax and decitabine, can help adults with T-cell acute lymphoblastic leukemia or lymphoma that has come back or not responded to treatment. The study will enroll 28 participants and measure how many achieve complete remission. The goal is to find a new option for this hard-to-treat cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: venetoclax and decitabine
What this could lead to: If successful, this combination could offer a new treatment option for patients whose T-cell leukemia/lymphoma has not responded to standard therapy.
What could go wrong: This is a small, early-phase trial with only 28 participants, so results may not apply broadly. The drugs can cause serious side effects like low blood counts and infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for T LYMPHOBLASTIC LEUKEMIA/LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lymphoma T lymphoblastic leukemia/lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

T LYMPHOBLASTIC LEUKEMIA/LYMPHOMA

Contacts and locations

Locations

Seoul National University Bundang Hospital
NOT_YET_RECRUITING

Seongnam-si, 13620, South Korea
Seoul National University Hospital
NOT_YET_RECRUITING

Seoul, 03080, South Korea
Seoul National University Hospital
RECRUITING

Seoul, 03080, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.